Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Journal
Experimental hematology & oncology
Journal Volume
12
Journal Issue
1
Pages
92
Date Issued
2023-10-16
Author(s)
Song, Yuqin
Shen, Zhixiang
Zhao, Donglu
Chan, Thomas Sau Yan
Huang, Huiqiang
Qiu, Lugui
Li, Jianyong
Tan, Tran-der
Zhu, Jun
Song, Yongping
Huang, Wei-Han
Zhao, Weili
Liu, Herman Sung Yu
Xu, Wei
Chen, Naizhi
Ma, Jun
Chang, Cheng-Shyong
Tse, Eric Wai Choi
Abstract
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies. Considering the unmet need of evidence on BTK inhibitors in all clinical settings and to standardize the use of BTK inhibitors available in mainland China, Taiwan, Hong Kong, and Macau regions, this consensus has been formulated for the treatment of various B-cell malignancies based on the clinical practice and available evidences on the use of BTK inhibitors. The recommendations of this consensus will provide guidance to physicians and clinical researchers on the effective treatment of B-cell malignancies with BTK inhibitors.
Subjects
BTK inhibitors; China; Consensus; Non-Hodgkin lymphoma; Targeted therapy
SDGs
Type
review